SavedAdd your journal

Journals / Türk Onkoloji Dergisi / 2020 / Cilt: 35 - Sayı: 1

Correlation of HER2/TOP2A Gene Aberrations with RASSF1A/APC Gene Methylation Status in High-Risk Breast Cancer

Oğuz ÇİLİNGİR
Ayşe Feyda NURSAL
Canan BAYDEMİR
Beyhan DURAK ARAS
Sevilhan ARTAN
Evrim ÇİFTCİ
Onur EROĞLU
Pages
8–14
Publication Date
2022-11-06
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

APC gene methylation was significantly more frequent intumors with TOP2A aberration (p=0.026).CONCLUSIONOur results suggested that APC gene promoter hypermethylation was associated with TOP2A geneaberrations in patients with high-risk BC.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:OBJECTIVEBreast cancer (BC) is a heterogeneous malignancy and differs widely among different patients.
📊
Key Findings & Data:The aimof this study was to investigate the relationship between the HER2/TOP2A gene aberrations and promoter methylation in RASSF1A/APC genes in patients with high-risk BC.METHODSFormalin-fixed paraffin embedded (FFPE) tissue samples from primary breast tumors (n=60) were assessed.
💡
Conclusion & Impact:APC gene methylation was significantly more frequent intumors with TOP2A aberration (p=0.026).CONCLUSIONOur results suggested that APC gene promoter hypermethylation was associated with TOP2A geneaberrations in patients with high-risk BC.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

OBJECTIVEBreast cancer (BC) is a heterogeneous malignancy and differs widely among different patients. The aimof this study was to investigate the relationship between the HER2/TOP2A gene aberrations and promoter methylation in RASSF1A/APC genes in patients with high-risk BC.METHODSFormalin-fixed paraffin embedded (FFPE) tissue samples from primary breast tumors (n=60) were assessed. HER2/TOP2A aberrations was evaluated using FISH method. DNA was extracted from FFPEtumor tissues, and Methylation-sensitive high resolution melting (MS-HRM) analysis were performedfor RASSF1A/APC genes methylation status.RESULTSHER2 amplification and TOP2A aberration were observed in 15/60 (25%) and 18/60 (30%) cases, respectively. According to the statistical analysis, HER2 amplification was associated with higher tumorgrade (p=0.001), PR status (p=0.025), and TOP2A aberrations (p=0.004). RASSF1A and APC methylation were 58/60 (96.6%) and 26/60 (43.3%), respectively. There was a significant correlation betweenAPC methylation and TOP2A aberration. APC gene methylation was significantly more frequent intumors with TOP2A aberration (p=0.026).CONCLUSIONOur results suggested that APC gene promoter hypermethylation was associated with TOP2A geneaberrations in patients with high-risk BC. This may be significant for targeted individual therapy. Additionally, it was confirmed that there was significant association of TOP2A gene aberrations with theHER2 gene amplification seen in BC.

🔖

Cite This Article

ÇİLİNGİR, O., NURSAL, A. F., BAYDEMİR, C., ARAS, B. D., ARTAN, S., ÇİFTCİ, E., EROĞLU, O. (2022). Correlation of HER2/TOP2A Gene Aberrations with RASSF1A/APC Gene Methylation Status in High-Risk Breast Cancer. Türk Onkoloji Dergisi, Cilt: 35 - Sayı: 1, 8–14. https://ajindex.com/articles/639175

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015;136(5):E359−86
  2. Canda T, Yavuz E, Ozdemir N, Ilvan S, Dizbay SS, Durak MG, et al. Immunohistochemical HER2 Status Evaluation in Breast Cancer Pathology Samples: A Multicenter, Parallel-Design Concordance Study. Eur J Breast Health 2018;14(3):160−5
  3. Di Cosimo S, Triulzi T, Pizzamiglio S, De Cecco L, de Azambuja E, Fumagalli D, et al. The 41-gene classifier TRAR predicts response of HER2 positive breast cancer patients in the NeoALTTO study. Eur J Cancer 2019;118:1−9
  4. Fountzilas G, Valavanis C, Kotoula V, Eleftheraki AG, Kalogeras KT, Tzaida O, et al.HER2 and TOP2A in highrisk early breast cancer patients treated with adjuvant epirubicin-based dose-dense sequential chemotherapy. J Transl Med 2012;10:10
  5. Eltohamy MI, Badawy OM, El kinaai N, Loay I, Nassar HR, Allam RM, et al. Topoisomerase II α Gene alteration in Triple Negative Breast Cancer and Its Predictive Role for Anthracycline-Based Chemotherapy (Egyptian NCI Patients).Asian Pac J Cancer Prev 2018;19(12):3581−9
  6. Akar RO, Selvi S, Ulukaya E, Aztopal N. Key actors in cancer therapy: epigenetic modifiers. Turk J Biol 2019;43(3):155−70
  7. Vu TL, Nguyen TT, Doan VTH, Vo LTT. Methylation Profiles of BRCA1, RASSF1A and GSTP1 in Vietnamese Women with Breast Cancer Asian Pac J Cancer Prev 2018;19:1887−93
  8. Feng W, Orlandi R, Zhao N, Carcangiu ML, Tagliabue E, Xu J,et al. Tumor suppressor genes are frequently methylated in lymph node metastases of breast cancers. BMC Cancer 2010;10:378
  9. Wang B, Song H, Jiang H, Fu Y, Ding X, Zhou C. Early diagnostic potential of APC hypermethylation in esophageal cancer. Cancer Manag Res 2018;10:181−98
  10. Jönsson M, Borg A, Nilbert M, Andersson T. Involvement of adenomatous polyposis coli (APC)/betacatenin signalling in human breast cancer. Eur J Cancer 2000;36(2):242−8
  11. Beser AR, Tuzlali S, Guzey D, Dolek Guler S, Hacihanefioglu S, et al. HER-2, TOP2A and Chromosome 17 Alterations in Breast Cancer. Pathol Oncol Res 2007;13(3):180−5
  12. Sunami E, Shinozaki M, Sim MS, Nguyen SL, Vu AT, Giuliano AE, et al. Estrogen receptor and Her2/neu status effect epigenetic differences of tumor-related genes in primary breast tumors. Breast Cancer Res 2008;10(3):R46
  13. Nami B, Maadi H, Wang Z. The Effects of Pertuzumab and Its Combination with Trastuzumab on HER2 Homodimerizat